Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Cancer statistics, 2014

2014 • 11,270 citations

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 • 11,185 citations

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

2004 • 9,201 citations

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

2009 • 7,749 citations

Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

2007 • 5,137 citations

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

2004 • 4,293 citations

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

2010 • 4,281 citations

Comprehensive genomic characterization of squamous cell lung cancers

2012 • 3,654 citations

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

2013 • 2,949 citations

First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer

2014 • 2,914 citations

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

2009 • 2,274 citations

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

2005 • 2,102 citations

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing

2013 • 1,940 citations

Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing

2012 • 1,734 citations

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

2012 • 1,480 citations

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

2008 • 1,306 citations

Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

2012 • 1,296 citations

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

2012 • 1,220 citations

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

2010 • 1,196 citations

Characterizing the cancer genome in lung adenocarcinoma

2007 • 1,110 citations

New driver mutations in non-small-cell lung cancer

2012 • 829 citations

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

2012 • 821 citations

KIF5B-RET fusions in lung adenocarcinoma

2012 • 785 citations

Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations

2011 • 668 citations

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions

2005 • 636 citations

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

2012 • 552 citations

American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non–Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy

2011 • 489 citations

Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis

2013 • 486 citations

Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

2011 • 470 citations

A Genomics-Based Classification of Human Lung Tumors

2013 • 467 citations

Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas

2012 • 430 citations

EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics

2013 • 408 citations

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

2010 • 392 citations

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials

2015 • 392 citations

Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER)

2014 • 380 citations

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice

2011 • 350 citations

Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions

2013 • 305 citations

Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study

2006 • 202 citations

Coexistence of PIK3CA and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling

2011 • 194 citations

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

2014 • 179 citations

Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

2012 • 176 citations

A Platform for Rapid Detection of Multiple Oncogenic Mutations With Relevance to Targeted Therapy in Non–Small-Cell Lung Cancer

2011 • 173 citations

Next-Generation Sequencing Reveals High Concordance of Recurrent Somatic Alterations Between Primary Tumor and Metastases From Patients With Non–Small-Cell Lung Cancer

2013 • 173 citations

Correlation between MET Gene Copy Number by Silver In Situ Hybridization and Protein Expression by Immunohistochemistry in Non-small Cell Lung Cancer

2012 • 150 citations

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

2009 • 139 citations

Characteristics of Lung Cancers Harboring NRAS Mutations

2013 • 135 citations

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

2014 • 125 citations

The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer

2012 • 108 citations

Systemic therapy of advanced non-small cell lung cancer: Major-developments of the last 5-years

2012 • 104 citations

Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing Panel

2014 • 103 citations

NCI-MATCH Launch Highlights New Trial Design in Precision-Medicine Era:

2015 • 103 citations

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer

2014 • 103 citations

Clinical significance of TTF‐1 protein expression and TTF‐1 gene amplification in lung adenocarcinoma

2008 • 102 citations

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

2012 • 101 citations

Prospective Clinical Study of Precision Oncology in Solid Tumors

2015 • 91 citations

Integration of Molecular Profiling into the Lung Cancer Clinic

2009 • 85 citations

Next-Generation Sequencing of Lung Cancer EGFR Exons 18-21 Allows Effective Molecular Diagnosis of Small Routine Samples (Cytology and Biopsy)

2013 • 82 citations

The GeneInsight suite: a platform to support laboratory and provider use of DNA-based genetic testing

2011 • 79 citations

What’s new in non-small cell lung cancer for pathologists the importance of accurate subtyping, EGFR mutations and ALK rearrangements

2011 • 67 citations

Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities

2013 • 43 citations

VeriStrat® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

2012 • 39 citations

ALK inhibitors and advanced non-small cell lung cancer (Review)

2014 • 36 citations

VeriStrat® has a prognostic value for patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab in the first line: Pooled analysis of SAKK19/05 and NTR528

2012 • 28 citations

Multi-Targeted Antiangiogenic Tyrosine Kinase Inhibitors in Advanced Non-Small Cell Lung Cancer: Meta-Analyses of 20 Randomized Controlled Trials and Subgroup Analyses

2014 • 21 citations

Magnitude of the Benefit of Progression-Free Survival as a Potential Surrogate Marker in Phase 3 Trials Assessing Targeted Agents in Molecularly Selected Patients with Advanced Non-Small Cell Lung Cancer: Systematic Review

2015 • 18 citations

From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with chemotherapy.

2011 • 14 citations

Diagnostic Value of Mutation-Specific Antibodies for Immunohistochemical Detection of Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer: A Meta-Analysis

2014 • 12 citations

Technology Assessment of Molecular Pathology Testing for the Estimation of Prognosis for Common Cancers

2014 • 4 citations